NEWS RELEASE | |
| For Immediate Release August 15, 2000 | |
South Africans Pay Less For Aids Drugs Than U.S. Patients
|
DALLAS (August 15, 2000) - In recent months the South African government has accused U.S. manufacturers of HIV/AIDS drugs of price gouging. But are they?
Not according to a new report be the National Center for Policy Analysis (NCPA SM), which notes that South Africa already pays some of the lowest prices found anywhere in the world.
"Far from being the victims of price gouging, South Africa is paying a fraction of the price the U.S. pays for drugs manufactured by American companies," said NCPA senior scholar Dorman Cordell. According to the report:
Although drug manufacturer prices in South Africa are among the lowest in the world, its retailers' markups in the private sector are among the highest. This is due in part to a cartel-like non-competitive retail market protected by government policy. For example:
"The South African private sector pays twice as much because its government discourages competition," said Cordell. "South Africa should reexamine its own policies before blaming others for its problems."
The NCPA is a research and educational organization operating under Section 501(c)(3) of the Internal Revenue Code. All contributions are tax deductible. We depend entirely on the financial support of individuals, corporations and foundations that believe in private sector solutions to public policy problems. We accept no government grants or contracts.
Sean Tuffnell, Dallas, TX 972-386-6272 Joan Kirby, Washington, DC 202-220-3082 Internet: http://www.ncpa.org Home | Support Us | All Issues | Social Security Debate Central | Contact Us |